🇺🇸 FDA
Pipeline program

PRG2302

PRG2302

Phase 1 small_molecule active

Quick answer

PRG2302 for Acute Lymphoblastic Leukemia is a Phase 1 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Acute Lymphoblastic Leukemia
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials